MedTrace Logo

Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy

NCT01946048 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-10-08

No results posted yet for this study

Summary

The aim of the present study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy .

Conditions

  • Ischemic Cardiomyopathy

Interventions

BIOLOGICAL

mesenchymal stem cells

Procedure: Selected patients were randomly divided into a cell therapy group and a control group. Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million.

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Principal Investigators

  • Baoyong Yan, Doctor · The First Hospital of Hebei Medical University

  • Gang Liu, Doctor · The First Hospital of Hebei Medical University

  • Guoping Ma, Master · The First Hospital of Hebei Medical University

  • Jun Zhang, Master · The First Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2013-10-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01946048 on ClinicalTrials.gov